Filing identity and reporting period
Important identity mismatch: The supplied filing is Magenta Therapeutics, Inc.’s Form 10-K, not Dianthus Therapeutics, Inc.’s filing. It covers the fiscal year ended December 31, 2022; it is not a quarterly report. Filed March 23, 2023.
Business context
Magenta was a pre-revenue biotechnology company developing therapies intended to improve stem-cell transplantation and conditioning. In February 2023, after year-end, it halted development across its programs, cut its workforce by 84%, and began a comprehensive review of strategic alternatives, including a company transaction or asset licensing/sales. If the review is unsuccessful, the board may consider dissolution and liquidation.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $55.1 million | $46.8 million |
| General and administrative expense | $25.8 million | $27.9 million |
| Total operating expenses / operating loss | $80.9 million | $74.7 million |
| Interest and other income, net | $4.4 million | $3.6 million |
| Net loss | $76.5 million | $71.1 million |
| Net loss per share | $1.29 | $1.29 |
| Cash used in operating activities | $67.1 million | $59.5 million |
At December 31, 2022, cash and cash equivalents were $57.6 million and marketable securities were $54.4 million, totaling approximately $112.0 million, down from $176.9 million at year-end 2021. Restricted cash was another $1.8 million. Accumulated deficit was $402.0 million; stockholders’ equity was $106.0 million. The balance sheet reported $40.7 million of total liabilities, including $30.0 million of operating lease liabilities. No conventional borrowings are identified in the supplied filing text.
There is no meaningful product margin information because the company had no product sales. Management stated that year-end cash, cash equivalents and marketable securities were expected to fund operating and capital needs for at least 12 months from the filing’s issuance date, subject to assumptions and the outcome of the strategic review. The company said expenses were expected to decline in 2023 following program stoppages and workforce reductions.
Material changes and unusual items
- Net loss increased by $5.3 million year over year; R&D expense rose $8.4 million, principally from conditioning-program spending on MGTA-45 and MGTA-117. G&A expense declined $2.2 million.
- Operating cash use increased $7.6 million. Financing cash inflow was $2.9 million in 2022, versus $89.6 million in 2021, when the company completed an $86.1 million net private placement.
- In 2022, the company sold 1.64 million shares through its ATM program for $2.8 million net. A further $47.0 million remained available under the ATM program at year-end, subject to market and other conditions.
- MGTA-117’s Phase 1/2 trial reported three suspected, unexpected serious adverse reactions. Two Cohort 4 participants had dose-limiting pulmonary toxicities; a Cohort 3 participant later experienced respiratory failure and cardiac arrest resulting in death, possibly related to treatment. Dosing was paused, the FDA placed the trial on partial clinical hold in February 2023, and the company discontinued the trial.
- The company also discontinued MGTA-145’s Phase 2 sickle-cell-disease trial and stopped certain MGTA-45 manufacturing and IND-enabling spending. Collaborations with bluebird bio, AVROBIO and Beam Therapeutics were terminated.
- The February 2023 restructuring was expected to generate approximately $5.4 million in severance and related costs. The Cambridge facility lease runs to February 2028; remaining minimum lease payments were $39.9 million, including $6.9 million due in 2023.
Outlook, risks and contingencies
Management’s immediate focus was the strategic alternatives process, not advancing clinical programs. No transaction was assured, and management warned that process costs would reduce cash available. If no transaction is completed, liquidation is possible; distributions to stockholders, if any, would depend on timing and reserves for obligations and contingencies. Strategic advisor Wedbush was entitled to a success fee of 1% of transaction value, subject to a $1.5 million minimum, upon a qualifying transaction.
Other notable risks include Nasdaq’s January 2023 notice that the share price had failed its $1.00 minimum bid-price requirement; the company had until July 31, 2023 to regain compliance. The filing also disclosed approximately $5.7 million on deposit with Silicon Valley Bank at year-end; after the bank’s closure and transfer of deposits to Silicon Valley Bridge Bank, the company reported approximately $36.9 million on deposit there as of March 20, 2023, including restricted cash. Lease commitments, licensing obligations, potential strategic-review costs, and the possibility that tax attributes may be limited are additional considerations.
Financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Confirm the issuer: this document is Magenta Therapeutics’ 2022 Form 10-K, not Dianthus Therapeutics’ filing.
- Check subsequent filings for the outcome of the strategic review, any asset sale or other transaction, and any liquidation decision or distribution estimate.
- Verify current cash balances, access to deposits, restructuring and advisory costs, and the actual runway after program shutdowns and lease obligations.
- Review developments regarding the MGTA-117 safety event and FDA partial clinical hold, and confirm the status of discontinued programs and terminated collaborations.
- Check Nasdaq listing status and any material changes to shares outstanding, financing capacity, or potential dilution.